The Biostatistics core serves as a resource to be called upon as needed by researchers participating in the University of Colorado Lung Cancer SPORE Grant. It offers consultation to both clinical and basic science researchers in a broad range of areas involving quantitative reasoning. This includes advice and implementation for statistical design, methodology and analysis issues, as well as epidemiological input and computing expertise. Core personnel will review all clinical protocols of the SPORE project and will write and oversee the statistical portions of these studies. The Biostatistics Core provides membership on the Protocol Review Committee of the Clinical Investigations Core for peer review of all Cancer Center and SPORE protocols. The Biostatistical core of the Lung Cancer SPORE is integrated into the Biostatistics Core of the Cancer Center. It will share its facilities, equipment and personnel to avoid duplication and for cost savings. A crucial aspect of the Lung Cancer SPORE is the evaluation of laboratory results in the clinical setting. This evaluation has clinical, statistical and epidemiologic components and implications. Examples are the prognostic importance of genetic and biological abnormalities, the sensitivity and specificity of new tests to detect dysplasia and early carcinomas, the relationships between different types of biological abnormalities, etc. The Biostatistics Core will assist in the design and evaluation of studies to ensure the scientific validity of these efforts. Where materials are gathered from national study groups, the core will work with the statistical centers of the national groups for the evaluation of biologic and clinical information. Through personnel with appointments in the Department of Preventive Medicine and Biometrics, researchers will have access, as needed, to more than 15 professionals in quantitative areas, in addition to those persons specifically assigned to the core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-03
Application #
3751701
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Ren, Shengxiang; Zhang, Shucai; Jiang, Tao et al. (2018) Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology 7:e1384108
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543

Showing the most recent 10 out of 435 publications